NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
34 hedge funds and large institutions have $1.94M invested in NeuBase Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
23% less funds holding
Funds holding: 44 → 34 (-10)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
59% less capital invested
Capital invested by funds: $4.74M → $1.94M (-$2.8M)
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
+$9.72K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$9.72K |
| 3 |
HF
HRT Financial
New York
|
+$4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.26K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$1.03K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$345K |
| 2 |
SCM
Sio Capital Management
New York
|
-$102K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$84K |
| 4 |
JAMONY
Jacob Asset Management of New York
Hermosa Beach,
California
|
-$40.4K |
| 5 |
Goldman Sachs
New York
|
-$32K |
NBSE Hedge Fund Activity: Q4 2022 in Review
34 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2022, worth a combined $1.94M — down 59% from $4.74M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NBSE and 3 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 5 added.
The largest buyer was Ergoteles, opening a new position worth an estimated $9.72K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $345K sold.
- 34 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2022, down from 44 in Q3 2022.
- Funds reported $1.94M of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2022, down 59% quarter-over-quarter.
- 3 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2022 and 13 closed out, a net change of -10 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2022 was Ergoteles, an estimated $9.72K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2022 was AIGH Capital Management, an estimated $345K sold.
Based on aggregated 13F filings for Q4 2022.